Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CV Safety Gets Diabetes Drugs Approved, Not Sold, AstraZeneca Exec Notes

Executive Summary

Firms shouldn't lose sight of the need to build the commercial aspects of their type 2 diabetes drugs as they focus on reorienting clinical trials to include cardiovascular risk assessment, according to an AstraZeneca exec

You may also be interested in...



Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says

Sponsors must move beyond glycemic control if they want any new therapy for type 2 diabetes to be commercially viable, according to a Roche executive.

Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says

Sponsors must move beyond glycemic control if they want any new therapy for type 2 diabetes to be commercially viable, according to a Roche executive.

AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared

AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel